Lyumjev (previously Liumjev) (insulin lispro)
- Region
- 🇪🇺 EU
- Active substance
- insulin lispro
- Company
- Eli Lilly Nederland B.V.
- Status
- Authorised
- Therapeutic area
- Diabetes Mellitus
- CHMP opinion
- Thu 30 Jan 2020
- EU approval
- Tue 24 Mar 2020
- Application
- EMEA/H/C/005037
- ATC
- A10AB04
- Official record
- www.ema.europa.eu
Indication
Treatment of diabetes mellitus in adults, adolescents and children aged 1 year and above.
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 Bysumlog Authorised · Sandoz GmbH
- 🇪🇺 Humalog Authorised · Eli Lilly Nederland B.V.
- 🇪🇺 Insulin lispro Sanofi Authorised · Sanofi Winthrop Industrie
- 🇪🇺 Liprolog Authorised · Eli Lilly Nederland B.V.
- 🇪🇺 Liprolog Withdrawn · Eli Lilly and Company Limited
Follow Lyumjev (previously Liumjev)
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.